Literature DB >> 31313971

Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application.

Om Prakash Singh1, Mallikarjuna Rao Gedda1, Shyam Lal Mudavath1,2, Onkar Nath Srivastava3, Shyam Sundar1.   

Abstract

Visceral leishmaniasis (VL) is a life-threatening parasitic disease affecting impoverished people of the developing world; and much effort has been spent on the early case detection and treatment. However, current diagnostics and treatment options are not sufficient for appropriate surveillance in VL elimination setting. Hence, there is a dire need to develop highly sensitive diagnostics and less toxic effective treatments for proper management of cases and to achieve the sustained disease elimination. Although, promising results have been observed with nanomedicines in leishmaniasis; there are great challenges ahead especially in translating this to clinical setting. This review provides updated progress of nanomedicines in VL, and discussed how these innovations and future directions play vital role in achieving VL elimination.

Entities:  

Keywords:  diagnostics; drug resistance; leishmaniasis; nano drug delivery; nanodiagnostics; nanomedicine; nanoparticles; nanotheranostics; treatment; visceral leishmaniasis

Mesh:

Substances:

Year:  2019        PMID: 31313971      PMCID: PMC7006826          DOI: 10.2217/nnm-2018-0448

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  74 in total

1.  Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani.

Authors:  Pramila Chaubey; Brahmeshwar Mishra; Shyam Lal Mudavath; Ravi R Patel; Sundeep Chaurasia; Shyam Sundar; Vasanti Suvarna; Marvis Monteiro
Journal:  Int J Biol Macromol       Date:  2018-01-04       Impact factor: 6.953

Review 2.  Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.

Authors:  Neeraj Tiwari; Mallikarjuna Rao Gedda; Vinod K Tiwari; Surya P Singh; Rakesh K Singh
Journal:  Mini Rev Med Chem       Date:  2018       Impact factor: 3.862

3.  Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis.

Authors:  Hafiz S Sarwar; Sehreen Ashraf; Sohail Akhtar; Muhammad F Sohail; Syed Z Hussain; Muhammad Rafay; Masoom Yasinzai; Irshad Hussain; Gul Shahnaz
Journal:  Nanomedicine (Lond)       Date:  2017-11-27       Impact factor: 5.307

4.  SPR analysis of the interaction between a recombinant protein of unknown function in Leishmania infantum immobilised on dendrimers and antibodies of the visceral leishmaniasis: A potential use in immunodiagnosis.

Authors:  Dênio E P Souto; Aliani M Fonseca; José T C Barragan; Rita de C S Luz; Hélida M Andrade; Flávio S Damos; Lauro T Kubota
Journal:  Biosens Bioelectron       Date:  2015-03-19       Impact factor: 10.618

Review 5.  Application of nanotechnology in treatment of leishmaniasis: A Review.

Authors:  Maryam Akbari; Ahmad Oryan; Gholamreza Hatam
Journal:  Acta Trop       Date:  2017-04-28       Impact factor: 3.112

Review 6.  Elimination of visceral leishmaniasis on the Indian subcontinent.

Authors:  Om Prakash Singh; Epco Hasker; Marleen Boelaert; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2016-09-28       Impact factor: 25.071

Review 7.  Applied Nanotoxicology.

Authors:  David W Hobson; Stephen M Roberts; Anna A Shvedova; David B Warheit; Georgia K Hinkley; Robin C Guy
Journal:  Int J Toxicol       Date:  2016 Jan-Feb       Impact factor: 2.032

8.  A novel self-assembled sandwich nanomedicine for NIR-responsive release of NO.

Authors:  Jing Fan; Nongyue He; Qianjun He; Yi Liu; Ying Ma; Xiao Fu; Yijing Liu; Peng Huang; Xiaoyuan Chen
Journal:  Nanoscale       Date:  2015-11-16       Impact factor: 7.790

9.  Leishmania donovani infection causes distinct epigenetic DNA methylation changes in host macrophages.

Authors:  Alexandra K Marr; Julia L MacIsaac; Ruiwei Jiang; Adriana M Airo; Michael S Kobor; W Robert McMaster
Journal:  PLoS Pathog       Date:  2014-10-09       Impact factor: 6.823

10.  Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis.

Authors:  Tapan Bhattacharyya; Duncan E Bowes; Sayda El-Safi; Shyam Sundar; Andrew K Falconar; Om Prakash Singh; Rajiv Kumar; Osman Ahmed; Marleen Boelaert; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2014-02-20
View more
  9 in total

1.  A chemical inhibitor of heat shock protein 78 (HSP78) from Leishmania donovani represents a potential antileishmanial drug candidate.

Authors:  Sonali Das; Anindyajit Banerjee; Mohd Kamran; Sarfaraz Ahmad Ejazi; Mohammad Asad; Nahid Ali; Saikat Chakrabarti
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

Review 2.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

3.  Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis.

Authors:  Nowsheen Goonoo; Marie Andrea Laetitia Huët; Itisha Chummun; Nancy Karuri; Kingsley Badu; Fanny Gimié; Jonas Bergrath; Margit Schulze; Mareike Müller; Archana Bhaw-Luximon
Journal:  R Soc Open Sci       Date:  2022-06-15       Impact factor: 3.653

4.  Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An in vitro and Preclinical Study.

Authors:  Mallikarjuna Rao Gedda; Prasoon Madhukar; Alok Kumar Vishwakarma; Vimal Verma; Anurag Kumar Kushwaha; Ganesh Yadagiri; Shyam Lal Mudavath; Om Prakash Singh; Onkar Nath Srivastava; Shyam Sundar
Journal:  Front Chem       Date:  2020-07-03       Impact factor: 5.221

Review 5.  Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Authors:  Arijit Bhattacharya; Audrey Corbeil; Rubens L do Monte-Neto; Christopher Fernandez-Prada
Journal:  Genes (Basel)       Date:  2020-06-29       Impact factor: 4.096

6.  Investigation of the antigenicity and protective efficacy of Leishmania promastigote membrane antigens in search of potential diagnostic and vaccine candidates against visceral leishmaniasis.

Authors:  Sarfaraz Ahmad Ejazi; Smriti Ghosh; Anirban Bhattacharyya; Mohd Kamran; Sonali Das; Sudipta Bhowmick; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  Parasit Vectors       Date:  2020-05-30       Impact factor: 3.876

Review 7.  Precision Medicine in Control of Visceral Leishmaniasis Caused by L. donovani.

Authors:  Eduard E Zijlstra
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

Review 8.  Nanodiagnostics in leishmaniasis: A new frontiers for early elimination.

Authors:  Mallikarjuna Rao Gedda; Prasoon Madhukar; Ashish Shukla; Shyam Lal Mudavath; Onkar Nath Srivastava; Om Prakash Singh; Shyam Sundar
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-03

9.  Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.

Authors:  Shabi Parvez; Ganesh Yadagiri; Mallikarjuna Rao Gedda; Aakriti Singh; Om Prakash Singh; Anurag Verma; Shyam Sundar; Shyam Lal Mudavath
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.